Currently out of the existing stock ratings of Geulah Livshits, 127 are a BUY (96.21%), 5 are a HOLD (3.79%).

Geulah Livshits

Work Performance Price Targets & Ratings Chart

Analyst Geulah Livshits, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 33.77% that have a potential upside of 40.29% achieved within 109 days.

Geulah Livshits’s has documented 255 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IPSC, Century Therapeutics at 07-Nov-2024.

Wall Street Analyst Geulah Livshits

Analyst best performing recommendations are on RCKT (ROCKET PHARMACEUTICALS).
The best stock recommendation documented was for RCKT (ROCKET PHARMACEUTICALS) at 12/8/2020. The price target of $46 was fulfilled within 1 day with a profit of $13.97 (43.62%) receiving and performance score of 436.15.

Average potential price target upside

of $48.39 (56.36%) on KRYS (KRYSTAL BIOTECH).
of $30.99 (82.2%) on NTLA (INTELLIA THERAPEUTICS).
of $19.74 (30.42%) on CRSP (CRISPR THERAPEUTICS AG).

CRSP Crispr Therapeutics AG EDIT Editas Medicine IOVA Iovance Biotherapeutics MRNA Moderna NTLA Intellia Therapeutics RCKT Rocket Pharmaceuticals RGNX Regenxbio KRYS Krystal Biotech SLDB Solid Biosciences LLC TSHA Taysha Gene Therapies VYGR Voyager Therapeutics FIXX Homology Medicines IMTX Immatics NV LOGC LogicBio Therapeutics TNYA Tenaya Therapeutics VINC Vincerx Pharma PRVB Provention Bio CABA Cabaletta Bio MGTX MeiraGTx Holdings PLC PASG Passage Bio SQZ Sqz Biotechnologies Co ACHL Achilles Therapeutics PLC ADR IMNM Immunome IMRX Immuneering Corp IPSC Century Therapeutics FDMT 4D Molecular Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Gena Wang (BARCLAYS)